2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3270 XPO1 malonylation indicates a drug-resistant state and predicts clinical outcome in multiple myeloma

Guangqi Wang, MD, PhD candidate, Fengjuan Fan2, Chi Ma, PhD3, Dehu Li4, Wang Jinhua5, Linyu Cai6, Wanting Yu, MD7, Lixin Quan8, Zhiqiang Liu9, Chunyan Sun10, Hu Yu, MD11
1 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
2 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
3 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
4 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
5 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
6 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
7 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
8 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
9 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
10 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
11 Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
Introduction:
Therapeutic resistance in multiple myeloma (MM) is increasingly recognized as a consequence of metabolic adaptation. While emerging lysine acylation modifications, including lysine malonylation (Kmal), have been implicated in cancer progression, their contribution to MM drug resistance remains poorly understood. A screening of lysine acylation modifications revealed significant enrichment of Kmal in BTZ-resistant MM cells, with malonylome analysis identifying XPO1 as a candidate functional substrate. Here, we investigated the role of XPO1 malonylation in MM drug resistance and explored its clinical relevance as a potential prognostic biomarker.

Methods:
Intracellular malonyl-CoA levels were quantified in MM cells and primary plasma cells by ELISA. Malonyl-CoA modulation, global lysine malonylation profiling, and malonyl-lysine–enriched proteomics were performed to identify resistance-associated malonylated proteins. XPO1 K→R mutants were generated to define functional malonylation sites, and the effects of XPO1 WT versus KR on BTZ and selinexor sensitivity were evaluated in vitro and in vivo. Integrated immunoprecipitation–mass spectrometry was performed to elucidate downstream mechanisms. To investigate clinical relevance, bone marrow biopsies from NDMM and RRMM patients were analyzed by CD138 and XPO1 Kmal immunohistochemistry, and XPO1 Kmal expression levels of malignant plasma cells were correlated with clinical characteristics and patient outcomes.

Results: 
Malonyl-CoA levels were significantly elevated in primary plasma cells from RRMM compared with NDMM, which were also observed in paired parental and drug-resistant MM cell lines. Supplementation of malonyl-CoA increased bortezomib resistance in MM cell lines. Consistently, global lysine malonylation levels were markedly increased in RRMM samples and resistant MM cell lines. Quantitative malonyl-proteomic profiling identified XPO1 as a resistance-associated protein with significantly enhanced malonylation in drug-resistant MM cells. Site-directed mutagenesis identified lysine 455 (K455) as the predominant functional malonylation site of XPO1, and a site-specific antibody against XPO1 K455mal was developed for further validation. MM cell lines expressing malonylation-deficient mutant XPO1 K455R exhibited enhanced sensitivity to bortezomib in vitro and in vivo compared with XPO1 WT-expressing cells. Loss of XPO1 malonylation did not alter XPO1 ubiquitination, phosphorylation, acetylation, or protein stability, suggesting a specific regulatory role of K455 malonylation. Immunoprecipitation–mass spectrometry revealed that XPO1 malonylation promoted Beclin1 nuclear export and autophagy activation under therapeutic stress, thereby maintaining cellular homeostasis and contributing to drug resistance.

Clinically, immunohistochemical analysis of bone marrow biopsies demonstrated significantly higher XPO1 K455mal levels in malignant plasma cells from RRMM patients compared with NDMM patients. Elevated XPO1 K455mal expression was associated with inferior clinical outcomes, suggesting its potential value as a prognostic biomarker for MM progression and treatment response.

Conclusions: 
XPO1 malonylation promotes therapeutic resistance in multiple myeloma. Elevated XPO1 malonylation levels in RRMM patients are associated with poor clinical outcomes, supporting its potential role as a prognostic biomarker and therapeutic vulnerability.
Guangqi Wang, MD, PhD candidate: No relevant conflicts of interest to declare.